Clinical trials: Immune Checkpoint Inhibitors
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
NSCLC, Melanoma
Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response
Immunotherapy with agents stimulating the immune system to act against cancer are now a new standard of care in various cancers as lung cancer and melanoma, but also bladder cancer, kidney cancer and head \& neck cancer.
- Conditions
- NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma
- Trial name
- NCT04146064
- Testing
- Breathprint analysis and patient-reported outcomes
- Where
- Canada
- Volunteers
- 190 people
- Sponsor
- University Health Network, Toronto
Non Small Cell Lung Cancer, Neoadjuvant Therapy
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy
A phase II, single-arm, open-label study evaluating feasibility, safety and efficacy of combined chemotherapy and pembrolizumab as neoadjuvant/adjuvant therapy in stage IIa-IIIB NSCLC adult patients followed by adjuvant PD-(L)1…
- Conditions
- Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor
- Trial name
- NeoP (NCT05383716)
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Endocrinopathy
Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy
To review cases from NTUH who developed endocrinopathy and metabolic diseases after immunotherapy, and statistically analyzed their age, clinical presentation, image findings, treatment and its response.
- Trial name
- NCT04079647
- Testing
- Immunotherapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Carcinoma, Non-Small-Cell Lung, Metastatic Lung Non-Small Cell Carcinoma
Palliative RadIotherapy of Multiple Metastatic Sites Before First Line of Systemic Therapy With Immune Checkpoint Inhibitors and Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
The study is designed as a non-randomized Phase 2 clinical intervention study. The study will include patients with disseminated Non-Small Cell Lung Carcinoma (NSCLC) which are eligible for first line of systemic treatment with…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Metastatic Lung Non-Small Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- PRIMM (NCT05440916)
- Testing
- Palliative Radiotherapy: 5 x 4Gy, chemotherapy + immune checkpoint inhibitors
- Where
- 3 sites in Slovenia
- Volunteers
- 50 people
- Sponsor
- University Medical Centre Maribor
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma
- Trial name
- ICONIC (NCT05229614)
- Testing
- Carbon Ion Therapy, Immunotherapy (Pembrolizumab)
- Where
- 4 sites in Germany, Italy
- Volunteers
- 27 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Malignant Ascites
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
- Trial name
- NCT05745233
- Testing
- Nivolumab, Pembrolizumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Neoplasms
BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAE
The study will collect leftover clinic blood samples on new oncology ICPI patients and test them for routine blood tests and malondialdehyde.
- Trial name
- NCT06247865
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Malignant Tumors
125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
This prospective randomized trial evaluates the efficacy and safety of combining 125I seed interstitial brachytherapy with immune checkpoint inhibitor therapy in patients with primary, recurrent, or metastatic malignant tumors.
- Trial name
- NCT07277777
- Testing
- Immune Checkpoint Inhibitors, 125I Seed Implantation
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Li Min
Gastric Cancer Stage IV
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
In this retrospective study, investigators conducted a comprehensive investigation of the factors influencing postoperative prognosis in patients with stage IV gastric cancer undergoing conversion surgery.
- Trial name
- NCT07009600
- Testing
- immune check point inhibitors (PD-1 inhibitors), target therapy (trastuzumab)
- Volunteers
- 124 people
- Sponsor
- Samsung Medical Center
HCC - Hepatocellular Carcinoma, Psychological Distress
The Impact of Emotional Stress on Immunotherapy Outcomes in Liver Cancer Patients: A Multi-Cohort Study
The goal of this observational study is to learn if emotional distress affects how well liver cancer treatment works in people receiving immunotherapy. Emotional distress means feeling anxious or depressed.
- Conditions
- HCC - Hepatocellular Carcinoma, Psychological Distress, Immune Checkpoint Inhibitors (ICIs), Cancer, Treatment-Related
- Trial name
- SOLACE (NCT07141056)
- Testing
- Psychological Stress Status
- Where
- 5 sites in China
- Volunteers
- 700 people
- Sponsor
- Guilin Medical University, China
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
This phase II clinical trial tests how well rigosertib plus pembrolizumab workings in treating patients with melanoma which cannot be removed by surgery (unresectable) or that has spread from where it first started (primary site)…
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Refractory Melanoma
- Trial name
- NCT05764395
- Testing
- Rigosertib, Pembrolizumab, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer
Current clinical trials testing the combination of immunotherapy with radiotherapy.
- Trial name
- REVIVE (NCT07603856)
- Testing
- Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Chicago
Gallbladder Cancer
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
The TOPAZ-1 study compared the advantages and disadvantages of immune checkpoint inhibitor anti-PD-L1 antibody combined with Gem/Cis chemotherapy (Gemcitabine and Cisplatin) and Gem/Cis chemotherapy alone in first-line treatment…
- Trial name
- NCT06013943
- Testing
- Envafolimab+Gemox
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Non-small Cell Lung Cancer
Neoadjuvant Immune Checkpoint Inhibitor Combined With Chemotherapy in Non-small Cell Lung Cancer
The primary object of this study is to determine tumor major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer who subjected to neoadjuvant immune checkpoint…
- Trial name
- NCT04945200
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Any Advanced Solid Tumors
Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events
The study will enroll patients with history of malignancy treated with immune checkpoint inhibitors (ICI) that have developed a grade 2 or higher immune related adverse event requiring treatment discontinuation as deemed by the…
- Trial name
- IRIS (NCT07836101)
- Testing
- Sarilumab, ICI Therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms, Immunotherapy
IMMUNO-FIT Observational Study
This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers.
- Conditions
- Neoplasms, Immunotherapy, Physical Fitness, Quality of Life
- Trial name
- NCT07354971
- Testing
- Observational Study - No Study Intervention
- Where
- United Kingdom
- Volunteers
- 67 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Endometrial Adenocarcinoma, Endometrial Cancer
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior…
- Trial name
- QLPPEC/GOG-003 (NCT06917092)
- Testing
- QL1706 combined with chemotherapy ± Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Neoplasms
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
This is a single arm, open phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab + irinotecan in the treatment of Ras wild-type recurrent and refractory colorectal cancer.
- Trial name
- NCT05143099
- Testing
- TEC
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Lung Neoplasm Malignant
Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]
This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of…
- Trial name
- BUDDY (NCT04059887)
- Testing
- Atezolizumab Injection [Tecentriq]
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Chonnam National University Hospital